Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present...
June 17, 2025 09:04 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases

NorthStrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases
May 22, 2025 08:16 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re
May 13, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22
April 29, 2025 12:15 ET | Source: PMGC Holdings Inc.

RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
April 29, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
April 28, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial

Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Pha
April 24, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment

Northstrive Biosciences Announces Positive FDA Pre-IND Response Supporting IND Submission of EL-22 to Conduct Phase 2 Clinical Trial for Obesity Treatment
April 10, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases
March 27, 2025 08:00 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market